The August 10 judgment from the Jinan Intermediate People's Court targets the masterForce simulation and ATreat design systems used in the company's A7 and A7 Speed products. Despite the court order, Angelalign CEO Fox Hu emphasized that the decision has no immediate operational impact on patients or dental providers. The company plans to contest the ruling, pointing to a recent victory in Germany where the Unified Patent Court rejected a similar preliminary injunction request regarding the same patent family.

This litigation is part of a broader, long-running patent infringement battle initiated by Align Technology. While the Chinese market faces this specific legal hurdle, Angelalign continues to expand its footprint, recently establishing a 52,000-square-foot manufacturing facility in the United States. With a market capitalization of $2 billion, the firm asserts that its history of clinical innovation and previous courtroom wins in Zhengzhou support its confidence in overturning the Jinan decision. The company remains focused on its global growth strategy, which now encompasses services in over 60 countries.